In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on G1 Therapeutics Inc (GTHX), with a price target of $72. The company’s shares closed yesterday at $20.69, close to its 52-week low of $13.87.
White commented:
“We base our $72 price target on probability-adjusted revenue forecasts for trilaciclib in first line SCLC, second and third line SCLC, and metastatic TNB cancer plus lerociclib in ER+, HER2- breast cancer and EGFR mutant NSCLC. We use the net present value of our revenue forecast through 2026, apply a 50% and 40% POS for trilaciclib and lerociclib, respectively, a 3x price/sales multiple, and a $2.35/share value for the early stage pipeline that includes trilaciclib and lerociclib in other indications, and G1T48.”
According to TipRanks.com, White is a 5-star analyst with an average return of 14.7% and a 48.5% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Aileron Therapeutics Inc.
G1 Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $63.50, implying a 206.9% upside from current levels. In a report issued on April 30, B.Riley FBR also reiterated a Buy rating on the stock with a $55 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $69.57 and a one-year low of $13.87. Currently, G1 Therapeutics Inc has an average volume of 319.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
G1 Therapeutics, Inc. develops drugs for cancer treatment. It is a clinical-stage biopharmaceutical company that focuses on the discovery and development of novel therapies to address significant unmet needs in oncology. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.
